Education
About Us
Working with TipRanks
Follow Us
BioLife Solutions (BLFS)
NASDAQ:BLFS
Top Page
BioLife Solutions
(NASDAQ:BLFS)
Select Model
Select Model
Rating:63Neutral
Price Target:
$26.00
▲(7.44% Upside)
Action:ReiteratedDate:02/28/26
The score is driven primarily by improving financial momentum (strong growth, solid margins, low leverage, and positive free cash flow) and a favorable earnings outlook pointing to potential first-time GAAP profitability in 2026. These positives are tempered by weak valuation signals tied to currently negative earnings and only mixed technical conditions, plus margin and concentration risks highlighted on the earnings call.
Positive Factors
Market leadership in BPM
BioLife's dominant placement of BPM in approved therapies and a >70% share in relevant CGT trials creates durable pull-through as therapies commercialize. This embedment raises switching costs, supports recurring demand and provides a structural moat that aids long-term revenue visibility and cross-sell.
Strong balance sheet and cash generation
A large cash position and a return to positive operating/free cash flow give BioLife financial flexibility to fund R&D, absorb short-term execution issues, repay modest SGD debt and pursue targeted M&A or partnerships. Low leverage materially reduces solvency risk while scaling commercial operations.
Clear guidance toward sustainable profitability
Management's explicit 2026 guidance for meaningful revenue growth, sustained mid‑60s gross margins and first full‑year GAAP profit signals operational leverage and execution confidence. If achieved, this marks a structural inflection from cash-positive adjustments to consistent GAAP earnings and margin durability.
Negative Factors
Customer and product concentration
Heavy reliance on a small set of BPM customers and on BPM as the core product line concentrates sales risk—loss, pricing pressure or procurement changes at a few customers would materially affect revenue. This concentration limits diversification and increases demand volatility risk.
Bag-yield issues creating margin drag
Operational bag-yield problems directly reduce gross margins and require a phased remediation with customer notifications and inventory sell-through, extending margin pressure into 2026. This technical manufacturing issue threatens margin sustainability until fully resolved and validated in the field.
Persistent GAAP losses and volatility
Although adjusted metrics and cash flow improved, recurring GAAP losses and historical volatility mean reported earnings sensitivity remains high. Dependence on nonrecurring items and variable product mix raises the risk that a single operational setback could reverse improvements and delay durable GAAP profitability.
BioLife Solutions (BLFS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.17B
Dividend YieldN/A
Average Volume (3M)363.00K
Price to Earnings (P/E)―
Beta (1Y)1.50
Revenue Growth-18.82%
EPS Growth92.56%
CountryUS
Employees159
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.04
Shares Outstanding48,300,000
10 Day Avg. Volume392,925
30 Day Avg. Volume363,004
Financial Highlights & Ratios
PEG Ratio2.20
Price to Book (P/B)3.10
Price to Sales (P/S)12.00
P/FCF Ratio57.40
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue12.22
Enterprise Value/Gross Profit18.93
Enterprise Value/Ebitda-146.66
Forecast
1Y Price Target
$33.20Price Target Upside37.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.1
Revenue Forecast (FY)$111.06M
BioLife Solutions Business Overview & Revenue Model
Company DescriptionBioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
How the Company Makes MoneyBioLife Solutions generates revenue primarily through the sale of its biopreservation products, which include cryopreservation media, storage containers, and automated thawing systems. The company also earns income from its proprietary technology licenses and research collaborations with pharmaceutical and biotechnology companies. Key revenue streams include direct product sales, partnerships with major players in the cell and gene therapy sectors, and ongoing contracts with research institutions. Significant partnerships with industry leaders enhance BioLife's market presence and contribute to its earnings by expanding its customer base and driving product adoption in various therapeutic applications.
BioLife Solutions Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call highlights strong top-line growth (29% YoY), significant improvement in adjusted EBITDA and a return to profitability, strengthened liquidity after divesting a product line, and clear 2026 guidance signaling continued growth and expected GAAP profitability. Notable challenges include a decline in gross margin driven by product mix and bag-yield issues (a 2–3 point gross margin headwind in H2 2025), customer/product concentration, a one-time tax true-up that boosted margins, and longer adoption cycles for strategic cross-sell and partnership initiatives. On balance, operational execution, cash position, market leadership in BPM, and improved profitability outweigh the headwinds, though the margin and concentration risks merit monitoring.Q4-2025 Updates
Positive Updates
Strong Revenue Growth
Total 2025 revenue grew 29% year-over-year to $96.2M; Q4 2025 revenue was $24.8M, up 20% year-over-year and landing at the high end of guidance.
Significant EBITDA and Profitability Improvement
Adjusted EBITDA for full-year 2025 increased to $25.0M (26% of revenue) from $13.3M (18% of revenue) in 2024. Q4 adjusted EBITDA was $6.9M (28% of revenue) versus $3.7M (18%) prior-year.
Turnaround to Positive Adjusted Operating and Net Income
Full-year adjusted operating income was $2.9M (vs. adjusted operating loss of $2.6M in 2024). Full-year adjusted net income was $6.3M (vs. adjusted net loss of $2.9M in 2024). Q4 adjusted net income was $1.9M (vs. adjusted net loss of $0.1M prior-year).
Healthy Liquidity and Balance Sheet Actions
Cash and marketable securities totaled $120.2M at 12/31/2025 (up from $105.4M at 12/31/2024). Cash increased in Q4 largely due to $23.5M cash proceeds from the divestiture of SAVSU; remaining SGD debt was $5.0M expected to be paid off by June 2026.
Clear 2026 Financial Guidance
2026 guidance calls for revenue of $112.5M–$115.0M (growth of 17%–20%), mid-60s gross margin, further adjusted EBITDA margin expansion, and expected full-year GAAP net income for the first time in many years.
Market Leadership in BPM and Commercial Traction
BPM accounted for ~85% of Q4 revenue; top 20 BPM customers ~80% of BPM revenue. BPM products embedded in 16 approved therapies and used in >250 relevant commercially sponsored CGT trials in the U.S. (representing >70% share), including >30 Phase 3 trials where share approaches ~80%.
Shift Toward Commercial Customers
Commercial BPM customers represented nearly 50% of revenue in 2025, up from the low-40s in 2024, improving visibility and supporting near- and long-term revenue predictability; management expects commercial mix to be ~50%–55% in 2026.
Operational and Strategic Initiatives
ERP manufacturing modules implemented with no disruption, enabling greater automation and controls. Strategic actions include acquisition of Panthera, investment in Pluristics, and a distribution/product development partnership with Qkine for cytokines and CellSeal vial integration.
Cross-Sell Opportunity
Management estimates that cross-selling additional cell processing tools to existing BPM customers could increase revenue per patient dose by 2x–3x over BPM alone; widespread adoption would be a multi-year opportunity and a strategic focus for 2026.
Negative Updates
Decline in Gross Margin
Adjusted gross margin decreased to 66% for full-year 2025 (from 69% in 2024) and 64% in Q4 2025 (vs. 67% prior-year), driven by product mix shift toward lower-margin bags and lower bag yields in H2.
Bag Yield Issues and Margin Headwind
Lower-than-anticipated bag yields in the second half created an estimated ~2–3 percentage-point headwind to gross margin. Management identified a solution but requires a 90-day customer notification and sell-through of higher-cost inventory, with expected remediation benefits around Q4 2026.
Concentration Risk in BPM Customer Base
BPM comprised ~85% of Q4 revenue and the top 20 BPM customers accounted for ~80% of BPM revenue, indicating customer and product concentration that raises demand and operational concentration risk.
HPL Media Flat Due to China Import Restrictions
The HPL media business was flat year-over-year in 2025, attributed to import restrictions in China (now reportedly abated), capping growth in that product line.
One-Time Benefit Inflated Margins
A $1.3M sales tax true-up recorded in Q4 had roughly a 500 basis-point impact on Q4 adjusted EBITDA margin and a ~100 basis-point impact on full-year adjusted EBITDA margin, indicating part of margin improvement was non-recurring.
Rising Operating Costs
Adjusted operating expenses rose to $59.3M in 2025 from $52.9M in 2024, reflecting increased R&D headcount and investment; management expects increased R&D and S&M spend in 2026 to support growth, partially offsetting margin expansion.
Long Adoption Cycles for New Products and Partnerships
Cross-sell and Qkine-related revenue are long-cycle initiatives: cytokine/CellSeal integration is a ~6–9 month development effort with meaningful pull-through not expected until late 2026/early 2027; therefore much of this is upside rather than assumed in 2026 guidance.
Fewer FDA Approvals in 2025 vs 2024
2025 saw fewer regulatory approvals relative to 2024, creating uncertainty; management expects up to five unique therapy approvals over the next 12 months but timing and outcomes remain uncertain and material to long-term demand.
Inventory and Mix Drag on Early 2026 Margins
Management expects gross margins to be generally in line with 2025 due to higher average selling prices offset by product mix (growth in other cell processing tools) and the need to sell through higher-cost bag inventory in early 2026.
Company Guidance
BioLife guided 2026 revenue of $112.5–$115.0 million (growth of 17%–20% vs 2025 revenue of $96.2M, which rose 29% YoY), expects GAAP and adjusted gross margins in the mid‑60s (vs 2025 adjusted gross margin of 66% and Q4’s 64%), anticipates further adjusted EBITDA margin expansion versus 2025’s $25.0M (26% of revenue; Q4 adjusted EBITDA $6.9M, 28%), and expects to report positive full‑year GAAP net income for the first time; the outlook is driven by demand from BPM customers and increased uptake of other tools, assumes commercial customers will represent ~50%–55% of revenue in 2026 (up from roughly 50% in 2025 and the low‑40s in 2024), takes into account a ~2–3‑point bag‑yield headwind in H2/2025 that management expects to remediate with benefits around Q4 2026, and notes a strong balance sheet ($120.2M cash and marketable securities at 12/31/2025), SGD debt of $5.0M to be paid by June 2026 (plus a $1.2M balloon), and 48.3M shares outstanding (50.2M fully diluted).BioLife Solutions Financial Statement Overview
Summary
Overall fundamentals are improving: strong 2025 revenue growth (~30% YoY), healthy gross margins (~65%), a very low-leverage balance sheet, and a meaningful rebound to positive operating/free cash flow (~$20M). Offsetting this, GAAP profitability remains a key gap with persistent net losses and historically volatile results.Income Statement
Revenue growth is strong in 2025 (up ~30% year over year) and gross margins remain healthy (~65%), showing solid pricing power and product economics. However, profitability is still the key gap: net losses persist (about -13% net margin in 2025), and results have been volatile over the period (large losses in 2022–2023). Overall, the income statement shows improving operations and scale, but not yet consistent bottom-line profitability.52
Neutral
Balance Sheet
The balance sheet is a clear strength with very low leverage: debt is modest relative to equity (debt-to-equity ~0.03 in 2025, improved from ~0.09 in 2024). Equity remains large versus total assets, providing financial flexibility. The main weakness is that returns on equity are still negative due to ongoing losses, meaning the capital base is not yet generating positive earnings.78
Positive
Cash Flow
Cash generation has improved meaningfully: operating cash flow and free cash flow are both positive in 2025 (~$20M), with very strong free cash flow growth versus 2024. This is a notable turnaround from negative operating and free cash flow in 2022–2023. The key concern is consistency—cash flow has been choppy historically—and profitability is still negative even as cash flow turns positive.70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 96.21M | 82.25M | 75.86M | 76.24M | 119.16M |
| Gross Profit | 62.12M | 53.67M | 46.75M | 46.91M | 28.85M |
| EBITDA | -9.38M | 1.53M | -45.24M | -124.18M | -16.65M |
| Net Income | -12.13M | -20.18M | -66.43M | -139.81M | -8.91M |
Balance Sheet | |||||
| Total Assets | 405.88M | 399.49M | 412.71M | 450.23M | 552.60M |
| Cash, Cash Equivalents and Short-Term Investments | 120.18M | 104.58M | 44.18M | 62.70M | 69.87M |
| Total Debt | 11.02M | 30.17M | 33.83M | 43.71M | 26.88M |
| Total Liabilities | 34.00M | 50.58M | 75.05M | 86.04M | 76.24M |
| Stockholders Equity | 371.89M | 348.91M | 337.66M | 364.19M | 480.75M |
Cash Flow | |||||
| Free Cash Flow | 20.11M | 5.20M | -18.88M | -18.87M | -13.22M |
| Operating Cash Flow | 20.11M | 8.43M | -12.50M | -8.49M | -4.84M |
| Investing Cash Flow | -71.54M | 58.30M | 17.84M | -58.12M | -12.64M |
| Financing Cash Flow | -10.92M | -6.78M | 10.59M | 16.32M | -2.78M |
BioLife Solutions Technical Analysis
Positive
24.20
Price Trends
23.91
Positive
25.16
Negative
24.23
Negative
Market Momentum
-0.22
Negative
58.78
Neutral
51.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLFS, the sentiment is Positive. The current price of 24.2 is above the 20-day moving average (MA) of 22.58, above the 50-day MA of 23.91, and below the 200-day MA of 24.23, indicating a neutral trend. The MACD of -0.22 indicates Negative momentum. The RSI at 58.78 is Neutral, neither overbought nor oversold. The STOCH value of 51.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BLFS.
BioLife Solutions Risk Analysis
BioLife Solutions disclosed 34 risk factors in its most recent earnings report. BioLife Solutions reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioLife Solutions Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.17B | -77.34 | -5.20% | ― | -18.82% | 92.56% | |
55 Neutral | $1.24B | -21.28 | 1.69% | ― | -9.49% | 58.97% | |
52 Neutral | $1.36B | -8.67 | -136.96% | ― | 62.06% | -41.97% | |
52 Neutral | $1.27B | -17.34 | -86.99% | ― | ― | -40.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $989.86M | -10.17 | -24.65% | ― | -32.42% | -540.37% | |
42 Neutral | $182.64M | -4.71 | -27.19% | ― | 30.55% | -340.19% |
* Healthcare Sector Average
BLFS
BioLife Solutions
24.20
-0.31
-1.26%
AZTA
Azenta
26.98
-14.13
-34.37%
STAA
Staar Surgical
19.90
3.43
20.83%
PLSE
Pulse Biosciences
18.73
0.86
4.81%
SMTI
Sanara MedTech
20.44
-12.38
-37.72%
KMTS
Kestra Medical Technologies Ltd.
23.28
2.29
10.91%
BioLife Solutions Corporate Events
Executive/Board Changes
BioLife Solutions announces planned retirement of key executive
Neutral
Jan 9, 2026
On January 8, 2026, BioLife Solutions, Inc. announced that its Chief Quality and Operations Officer, Karen Foster, will retire from her role effective March 31, 2026. The company emphasized that her retirement is not due to any disagreement regarding its operations, policies, or practices, and expressed appreciation for her contributions, suggesting a planned leadership transition with no indicated disruption to ongoing business activities.
The most recent analyst rating on (BLFS) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on BioLife Solutions stock, see the BLFS Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.